NAMS Menopause Certification Exam Prep Document |
2026/2027 Edition | 250 Verified Questions
NAMS Menopause Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide is meticulously crafted for candidates preparing for the North
American Menopause Society (NAMS) Menopause Certification Exam. It features 250 verified
questions with detailed rationales, reflecting the most current evidence-based guidelines and clinical
practices. The content is organized to cover all essential domains, ensuring a thorough review of
menopause management, hormonal therapies, and associated health risks. With this resource, you will
gain the confidence and knowledge required to excel on the exam and enhance your clinical expertise.
Key Features:
Menopause physiology and transition stages
Pharmacologic and non-pharmacologic treatments
Hormone therapy: indications, risks, and benefits
Management of vasomotor symptoms and genitourinary syndrome
Long-term health implications: osteoporosis, cardiovascular, cognitive
Patient counseling and shared decision-making
Updates for 2026:
- Incorporate 2026 NAMS position statement updates
- Revised hormone therapy safety data and prescribing guidelines
- New evidence on non-hormonal alternatives for symptom management
- Updated cardiovascular risk assessment algorithms
- Enhanced focus on individualized, patient-centered care
Abstract:
The NAMS Menopause Certification Exam represents a rigorous assessment of a clinician's proficiency in the
comprehensive care of menopausal women. This preparatory document offers a curated collection of 250
questions, each accompanied by a detailed rationale that explains the correct answer and contextualizes the
underlying physiology and clinical evidence. The content is systematically organized to mirror the exam blueprint,
covering the biology of menopause, diagnostic criteria, therapeutic interventions, and the nuanced management of
complex cases. Special emphasis is placed on the latest hormonal therapy guidelines, including cardiovascular and
breast cancer risk considerations, as well as non-hormonal strategies for symptom relief. By engaging with these
materials, candidates will not only reinforce their existing knowledge but also identify areas requiring further
study. The rationales are designed to promote deep understanding, critical thinking, and the application of
evidence-based practice in real-world clinical scenarios. This guide serves as an indispensable tool for achieving
certification and delivering optimal care to menopausal patients.
Keywords:
Menopause certification, NAMS exam prep, Hormone therapy, Vasomotor symptoms, Genitourinary syndrome,
Osteoporosis prevention, Menopause management, Evidence-based practice
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a comprehensive
rationale. The rationale explains why the correct answer is right and why the distractors are incorrect, often
referencing clinical guidelines and research. This format reinforces learning and clarifies common misconceptions.
Compliance Checklist:
Page 1
, Aligned with NAMS 2026 updated guidelines
Covers all exam blueprint domains
Includes 250 unique, high-yield questions
Rationales cite evidence-based sources
Suitable for self-assessment and group study
Updated for the 2026-2027 exam cycle
Content Area Overview:
Content Area Questions Key Topics Weight
Menopause Physiology and 1-40 Stages of menopause, hormonal changes, 16%
Transition symptoms, diagnosis
Hormone Therapy 41-90 Types, regimens, indications, 20%
contraindications, risks/benefits
Non-Hormonal Management 91-130 Lifestyle, complementary therapies, 16%
prescription non-hormonal agents
Genitourinary Syndrome of 131-160 Symptoms, diagnosis, local therapies, 12%
Menopause (GSM) management
Long-Term Health and 161-210 Osteoporosis, cardiovascular risk, cognitive 20%
Prevention health, cancer screening
Patient Counseling and Special 211-250 Shared decision-making, premature 16%
Populations menopause, breast cancer survivors
Page 2
,Q1. Which hormonal pattern is most characteristic of the early menopausal transition
(Stage -3b per STRAW+10)?
A. Persistently elevated FSH with low AMH and undetectable inhibin B
B. Variable cycle length with elevated FSH in the follicular phase and normal luteal
phase progesterone
C. Anovulatory cycles with low progesterone and FSH within normal range
D. Rapid decline in estradiol with FSH >25 IU/L on two occasions
Correct Answer: B. Variable cycle length with elevated FSH in the follicular phase
and normal luteal phase progesterone
Rationale: The early menopausal transition is marked by variable cycle lengths and
elevated early follicular phase FSH, but ovulation often still occurs, so luteal progesterone
may be normal. Persistent FSH elevation and undetectable inhibin B are later changes.
Anovulation and low progesterone are more typical of late transition.
Why Wrong:
A - Persistently elevated FSH with low AMH is a hallmark of late transition, not
early.
C - Anovulatory cycles with low progesterone occur in late transition, not early.
D - FSH >25 IU/L on two occasions is a criterion for late transition, not early.
Reference: Harlow SD et al. STRAW+10. Menopause. 2012.
Q2. A postmenopausal woman with osteopenia (T-score -1.8) and vasomotor
symptoms requests hormone therapy. Which factor most strongly influences the
decision to initiate systemic estrogen?
A. Her age at menopause onset
B. Her 10-year fracture risk by FRAX
C. Her baseline cardiovascular risk profile
D. Her preference for oral versus transdermal route
Correct Answer: C. Her baseline cardiovascular risk profile
Rationale: Baseline cardiovascular risk is the key determinant of the risk-benefit ratio for
systemic estrogen, especially in older women or those with risk factors. Age at menopause
and fracture risk are important but secondary; route preference is a shared decision but
not the primary determinant.
Why Wrong:
A - Age at menopause influences absolute risks but is not the strongest factor.
B - Fracture risk is relevant but does not outweigh cardiovascular risk in
decision-making.
D - Route preference is a patient preference, not a medical determinant.
Reference: NAMS Position Statement. Menopause. 2022.
Page 3
, Q3. Which statement best reflects the current evidence on the use of compounded
bioidentical hormone therapy (cBHT)?
A. cBHT is FDA-approved and has undergone rigorous efficacy testing for menopause
symptoms
B. cBHT formulations are standardized but lack long-term safety data
C. cBHT offers unique benefits over FDA-approved therapies due to custom dosing
D. cBHT is not FDA-approved and has variable potency, and its use is discouraged by
NAMS
Correct Answer: D. cBHT is not FDA-approved and has variable potency, and its use
is discouraged by NAMS
Rationale: Compounded bioidentical hormones are not FDA-approved, lack
standardization, and have variable potency. NAMS recommends against their use because
of safety and efficacy concerns. They are not superior to approved therapies.
Why Wrong:
A - cBHT is not FDA-approved.
B - cBHT formulations are not standardized.
C - No evidence supports unique benefits over approved therapies.
Reference: NAMS Position Statement on Compounded Bioidentical Hormones. 2018.
Q4. A woman with a history of breast cancer (ER+) and severe vasomotor symptoms
is considering non-hormonal options. Which agent has the strongest evidence for
reducing hot flashes in this population?
A. Venlafaxine 37.5 mg daily
B. Gabapentin 300 mg at bedtime
C. Oxybutynin 2.5 mg twice daily
D. Paroxetine 10 mg daily
Correct Answer: A. Venlafaxine 37.5 mg daily
Rationale: Venlafaxine is a first-line non-hormonal option for breast cancer survivors,
with robust evidence for reducing hot flash frequency and severity. Gabapentin and
oxybutynin are alternatives, but venlafaxine has the strongest evidence. Paroxetine is
contraindicated with tamoxifen due to CYP2D6 inhibition.
Why Wrong:
B - Gabapentin is effective but not as strong as venlafaxine in this context.
C - Oxybutynin is effective but has less robust evidence in breast cancer survivors.
D - Paroxetine is contraindicated with tamoxifen due to drug interaction.
Reference: NAMS Guidelines. Menopause. 2023.
Page 4
2026/2027 Edition | 250 Verified Questions
NAMS Menopause Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide is meticulously crafted for candidates preparing for the North
American Menopause Society (NAMS) Menopause Certification Exam. It features 250 verified
questions with detailed rationales, reflecting the most current evidence-based guidelines and clinical
practices. The content is organized to cover all essential domains, ensuring a thorough review of
menopause management, hormonal therapies, and associated health risks. With this resource, you will
gain the confidence and knowledge required to excel on the exam and enhance your clinical expertise.
Key Features:
Menopause physiology and transition stages
Pharmacologic and non-pharmacologic treatments
Hormone therapy: indications, risks, and benefits
Management of vasomotor symptoms and genitourinary syndrome
Long-term health implications: osteoporosis, cardiovascular, cognitive
Patient counseling and shared decision-making
Updates for 2026:
- Incorporate 2026 NAMS position statement updates
- Revised hormone therapy safety data and prescribing guidelines
- New evidence on non-hormonal alternatives for symptom management
- Updated cardiovascular risk assessment algorithms
- Enhanced focus on individualized, patient-centered care
Abstract:
The NAMS Menopause Certification Exam represents a rigorous assessment of a clinician's proficiency in the
comprehensive care of menopausal women. This preparatory document offers a curated collection of 250
questions, each accompanied by a detailed rationale that explains the correct answer and contextualizes the
underlying physiology and clinical evidence. The content is systematically organized to mirror the exam blueprint,
covering the biology of menopause, diagnostic criteria, therapeutic interventions, and the nuanced management of
complex cases. Special emphasis is placed on the latest hormonal therapy guidelines, including cardiovascular and
breast cancer risk considerations, as well as non-hormonal strategies for symptom relief. By engaging with these
materials, candidates will not only reinforce their existing knowledge but also identify areas requiring further
study. The rationales are designed to promote deep understanding, critical thinking, and the application of
evidence-based practice in real-world clinical scenarios. This guide serves as an indispensable tool for achieving
certification and delivering optimal care to menopausal patients.
Keywords:
Menopause certification, NAMS exam prep, Hormone therapy, Vasomotor symptoms, Genitourinary syndrome,
Osteoporosis prevention, Menopause management, Evidence-based practice
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a comprehensive
rationale. The rationale explains why the correct answer is right and why the distractors are incorrect, often
referencing clinical guidelines and research. This format reinforces learning and clarifies common misconceptions.
Compliance Checklist:
Page 1
, Aligned with NAMS 2026 updated guidelines
Covers all exam blueprint domains
Includes 250 unique, high-yield questions
Rationales cite evidence-based sources
Suitable for self-assessment and group study
Updated for the 2026-2027 exam cycle
Content Area Overview:
Content Area Questions Key Topics Weight
Menopause Physiology and 1-40 Stages of menopause, hormonal changes, 16%
Transition symptoms, diagnosis
Hormone Therapy 41-90 Types, regimens, indications, 20%
contraindications, risks/benefits
Non-Hormonal Management 91-130 Lifestyle, complementary therapies, 16%
prescription non-hormonal agents
Genitourinary Syndrome of 131-160 Symptoms, diagnosis, local therapies, 12%
Menopause (GSM) management
Long-Term Health and 161-210 Osteoporosis, cardiovascular risk, cognitive 20%
Prevention health, cancer screening
Patient Counseling and Special 211-250 Shared decision-making, premature 16%
Populations menopause, breast cancer survivors
Page 2
,Q1. Which hormonal pattern is most characteristic of the early menopausal transition
(Stage -3b per STRAW+10)?
A. Persistently elevated FSH with low AMH and undetectable inhibin B
B. Variable cycle length with elevated FSH in the follicular phase and normal luteal
phase progesterone
C. Anovulatory cycles with low progesterone and FSH within normal range
D. Rapid decline in estradiol with FSH >25 IU/L on two occasions
Correct Answer: B. Variable cycle length with elevated FSH in the follicular phase
and normal luteal phase progesterone
Rationale: The early menopausal transition is marked by variable cycle lengths and
elevated early follicular phase FSH, but ovulation often still occurs, so luteal progesterone
may be normal. Persistent FSH elevation and undetectable inhibin B are later changes.
Anovulation and low progesterone are more typical of late transition.
Why Wrong:
A - Persistently elevated FSH with low AMH is a hallmark of late transition, not
early.
C - Anovulatory cycles with low progesterone occur in late transition, not early.
D - FSH >25 IU/L on two occasions is a criterion for late transition, not early.
Reference: Harlow SD et al. STRAW+10. Menopause. 2012.
Q2. A postmenopausal woman with osteopenia (T-score -1.8) and vasomotor
symptoms requests hormone therapy. Which factor most strongly influences the
decision to initiate systemic estrogen?
A. Her age at menopause onset
B. Her 10-year fracture risk by FRAX
C. Her baseline cardiovascular risk profile
D. Her preference for oral versus transdermal route
Correct Answer: C. Her baseline cardiovascular risk profile
Rationale: Baseline cardiovascular risk is the key determinant of the risk-benefit ratio for
systemic estrogen, especially in older women or those with risk factors. Age at menopause
and fracture risk are important but secondary; route preference is a shared decision but
not the primary determinant.
Why Wrong:
A - Age at menopause influences absolute risks but is not the strongest factor.
B - Fracture risk is relevant but does not outweigh cardiovascular risk in
decision-making.
D - Route preference is a patient preference, not a medical determinant.
Reference: NAMS Position Statement. Menopause. 2022.
Page 3
, Q3. Which statement best reflects the current evidence on the use of compounded
bioidentical hormone therapy (cBHT)?
A. cBHT is FDA-approved and has undergone rigorous efficacy testing for menopause
symptoms
B. cBHT formulations are standardized but lack long-term safety data
C. cBHT offers unique benefits over FDA-approved therapies due to custom dosing
D. cBHT is not FDA-approved and has variable potency, and its use is discouraged by
NAMS
Correct Answer: D. cBHT is not FDA-approved and has variable potency, and its use
is discouraged by NAMS
Rationale: Compounded bioidentical hormones are not FDA-approved, lack
standardization, and have variable potency. NAMS recommends against their use because
of safety and efficacy concerns. They are not superior to approved therapies.
Why Wrong:
A - cBHT is not FDA-approved.
B - cBHT formulations are not standardized.
C - No evidence supports unique benefits over approved therapies.
Reference: NAMS Position Statement on Compounded Bioidentical Hormones. 2018.
Q4. A woman with a history of breast cancer (ER+) and severe vasomotor symptoms
is considering non-hormonal options. Which agent has the strongest evidence for
reducing hot flashes in this population?
A. Venlafaxine 37.5 mg daily
B. Gabapentin 300 mg at bedtime
C. Oxybutynin 2.5 mg twice daily
D. Paroxetine 10 mg daily
Correct Answer: A. Venlafaxine 37.5 mg daily
Rationale: Venlafaxine is a first-line non-hormonal option for breast cancer survivors,
with robust evidence for reducing hot flash frequency and severity. Gabapentin and
oxybutynin are alternatives, but venlafaxine has the strongest evidence. Paroxetine is
contraindicated with tamoxifen due to CYP2D6 inhibition.
Why Wrong:
B - Gabapentin is effective but not as strong as venlafaxine in this context.
C - Oxybutynin is effective but has less robust evidence in breast cancer survivors.
D - Paroxetine is contraindicated with tamoxifen due to drug interaction.
Reference: NAMS Guidelines. Menopause. 2023.
Page 4
